3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303
China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...
Deals
CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion
CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...
Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership
China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...
Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development
China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...
Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered...
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica,...
Ouro Medicines Launches with $120M Series A Financing for CM336 Development
Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.’s (HKG: 2162) CM336, has successfully launched...
Menarini Group Expands Oncology Pipeline with Insilico Medicine License
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...
Zai Lab Secures Rights to Vertex’s Povetacicept in Key Asian Markets
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced an exclusive collaboration and...
Eli Lilly in Advanced Talks to Acquire Scorpion Therapeutics for $2.5 Billion
US-based Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks with compatriot firm...
Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...
Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...
Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...
Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development
China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...
Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109
China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...
Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19
Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...
Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors
On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation...
Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions
US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership...